Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.
You may also be interested in...
Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues
FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD
NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA
Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate
Lunesta Crossover Trial Design, Unblinding By Taste Raised As Review Issues
FDA should re-consider its preference for parallel group rather than crossover trial designs in sleep drug development programs, according to FDA Office of Drug Evaluation I Director Robert Temple, MD